Research Training Group 2154 - Materials for Brain

Dr. med. Carolin Kubelt

Department for Neurosurgery, UKSH, Campus Kiel

Neuroimplants for glioblastoma therapy

Glioblastoma multiforme (GBM) represents the most common and most malign primary brain tumor in adults. Despite all research efforts and far-reaching technological advances in recent decades, no curative treatment strategies exist. Among other factors, this disastrous prognosis is as a result of early migration of tumor cells into the surrounding brain parenchyma. Thus, the invasive character of the tumor makes complete microscopic resection impossible. Furthermore, the postoperative administration of the commonly used chemotherapeutic agent, temozolomide, is to some extent limited by systemic side effects which can cause the need to pause or even stop the treatment. Nevertheless, resection followed by radiation and chemotherapy still represent the most effective therapy regime till date. A promising treatment strategy is the local administration of chemotherapy through a neuro-implant. This opens the opportunity to overcome systemic toxicity of the chemotherapeutic agent and reach remaining tumor cells after resection. Within the framework of this project, newly developed neuro-implants loaded with chemotherapy will be exanimated in vivo. Since tumor metabolism also contributes to the aggressive behavior of GBM, further molecular analyses of human glioma samples will take place to broaden the understanding of this disease. Altogether, our aim is to contribute to an improvement of the disastrous prognosis of this neoplasm.